The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice
(2017) In Pharmacology, Biochemistry and Behavior 160. p.14-20- Abstract
Glucagon-like peptide-1 (GLP-1) is a gut peptide that regulates food intake and glucose metabolism. GLP-1 is also produced and released in the brain, and GLP-1 receptors are expressed in brain regions important for alcohol and drug reward, and for the development of addiction. GLP-1 receptor agonists can decrease alcohol intake acutely in rodents. However, alcohol use disorder is a chronic condition that requires treatments to be effective in promoting abstinence from excessive alcohol consumption over time. Here, we assessed the effect of daily treatment with the GLP-1 receptor agonist Exendin-4 in an assay of relapse-like drinking in socially housed mice. Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant... (More)
Glucagon-like peptide-1 (GLP-1) is a gut peptide that regulates food intake and glucose metabolism. GLP-1 is also produced and released in the brain, and GLP-1 receptors are expressed in brain regions important for alcohol and drug reward, and for the development of addiction. GLP-1 receptor agonists can decrease alcohol intake acutely in rodents. However, alcohol use disorder is a chronic condition that requires treatments to be effective in promoting abstinence from excessive alcohol consumption over time. Here, we assessed the effect of daily treatment with the GLP-1 receptor agonist Exendin-4 in an assay of relapse-like drinking in socially housed mice. Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37 days. Then, alcohol bottles were removed and Exendin-4 (1.5 μg/kg/day) or saline was administered subcutaneously for 8 days during alcohol deprivation. Treatment continued for 8 additional days after reintroducing access to alcohol. A high-precision automated fluid consumption system was used to monitor intake of alcohol and water, drinking kinetics, and locomotor activity. Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity. The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected. The effect was maintained undiminished throughout the treatment period. These findings support the possible use of GLP-1 receptor agonists in the treatment of alcohol use disorder.
(Less)
- author
- Thomsen, Morgane ; Dencker, Ditte ; Wörtwein, Gitta ; Weikop, Pia ; Egecioglu, Emil LU ; Jerlhag, Elisabet ; Fink-Jensen, Anders and Molander, Anna
- organization
- publishing date
- 2017-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alcohol deprivation, Alcoholism, Ethanol, Exenatide, Group-housed, Incretin hormones
- in
- Pharmacology, Biochemistry and Behavior
- volume
- 160
- pages
- 7 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:28778739
- wos:000412617800002
- scopus:85026833408
- ISSN
- 0091-3057
- DOI
- 10.1016/j.pbb.2017.07.014
- language
- English
- LU publication?
- yes
- id
- 3241fa86-be58-4050-ad43-2e32424e98cd
- date added to LUP
- 2017-08-29 11:15:42
- date last changed
- 2025-03-19 06:15:10
@article{3241fa86-be58-4050-ad43-2e32424e98cd,
abstract = {{<p>Glucagon-like peptide-1 (GLP-1) is a gut peptide that regulates food intake and glucose metabolism. GLP-1 is also produced and released in the brain, and GLP-1 receptors are expressed in brain regions important for alcohol and drug reward, and for the development of addiction. GLP-1 receptor agonists can decrease alcohol intake acutely in rodents. However, alcohol use disorder is a chronic condition that requires treatments to be effective in promoting abstinence from excessive alcohol consumption over time. Here, we assessed the effect of daily treatment with the GLP-1 receptor agonist Exendin-4 in an assay of relapse-like drinking in socially housed mice. Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37 days. Then, alcohol bottles were removed and Exendin-4 (1.5 μg/kg/day) or saline was administered subcutaneously for 8 days during alcohol deprivation. Treatment continued for 8 additional days after reintroducing access to alcohol. A high-precision automated fluid consumption system was used to monitor intake of alcohol and water, drinking kinetics, and locomotor activity. Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity. The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected. The effect was maintained undiminished throughout the treatment period. These findings support the possible use of GLP-1 receptor agonists in the treatment of alcohol use disorder.</p>}},
author = {{Thomsen, Morgane and Dencker, Ditte and Wörtwein, Gitta and Weikop, Pia and Egecioglu, Emil and Jerlhag, Elisabet and Fink-Jensen, Anders and Molander, Anna}},
issn = {{0091-3057}},
keywords = {{Alcohol deprivation; Alcoholism; Ethanol; Exenatide; Group-housed; Incretin hormones}},
language = {{eng}},
month = {{09}},
pages = {{14--20}},
publisher = {{Elsevier}},
series = {{Pharmacology, Biochemistry and Behavior}},
title = {{The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice}},
url = {{http://dx.doi.org/10.1016/j.pbb.2017.07.014}},
doi = {{10.1016/j.pbb.2017.07.014}},
volume = {{160}},
year = {{2017}},
}